0001370053false00013700532023-10-252023-10-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: October 25, 2023
(Date of earliest event reported)

ANAPTYSBIO, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware001-3798520-3828755
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
            
10770 Wateridge Circle, Suite 210,
San Diego, CA 92121
(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANAB
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 7.01. Regulation FD.
On October 25, 2023, AnaptysBio presented its PD-1 Agonist (Rosnilimab) R&D slide presentation, a full copy of which is attached hereto as Exhibit 99.1.
The information in this item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberExhibit Title or Description
AnaptysBio PD-1 Agonist (Rosnilimab) R&D Slide Presentation October 2023.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                   
AnaptysBio, Inc.
Date: October 25, 2023By:/s/Dennis Mulroy
Name: Dennis Mulroy
Title: Chief Financial Officer



slide1.jpg



slide2.jpg



slide3.jpg



slide4.jpg



slide5.jpg



slide6.jpg



slide7.jpg



slide8.jpg



slide9.jpg



slide10.jpg



slide11.jpg



slide12.jpg



slide13.jpg



slide14.jpg



slide15.jpg



slide16.jpg



slide17.jpg



slide18.jpg



slide19.jpg



slide20.jpg



slide21.jpg



slide22.jpg



slide23.jpg



slide24.jpg



slide25.jpg



slide26.jpg



slide27.jpg



slide28.jpg



slide29.jpg



slide30.jpg



slide31.jpg



slide32.jpg



slide33.jpg



slide34.jpg



slide35.jpg



slide36.jpg



slide37.jpg



slide38.jpg



slide39.jpg



slide40.jpg



slide41.jpg



slide42.jpg



slide43.jpg



slide44.jpg



slide45.jpg



slide46.jpg



slide47.jpg



slide48.jpg



slide49.jpg



slide50.jpg



slide51.jpg



slide52.jpg



slide53.jpg



slide54.jpg



slide55.jpg



slide56.jpg



slide57.jpg



slide58.jpg



slide59.jpg



slide60.jpg



slide61.jpg



slide62.jpg



slide63.jpg



slide64.jpg



slide65.jpg



slide66.jpg



slide67.jpg



slide68.jpg



slide69.jpg



slide70.jpg



slide71.jpg

v3.23.3
Cover Page
Oct. 25, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 25, 2023
Entity Registrant Name ANAPTYSBIO, INC
Entity Incorporation, State or Country Code DE
Entity File Number 001-37985
Entity Tax Identification Number 20-3828755
Entity Address, Address Line One 10770 Wateridge Circle
Entity Address, Address Line Two Suite 210,
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 362-6295
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ANAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001370053
Amendment Flag false
Document Information [Line Items]  
Document Type 8-K
Entity Addresses [Line Items]  
Entity Address, Address Line One 10770 Wateridge Circle
Entity Address, Address Line Two Suite 210,
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121

AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more AnaptysBio Charts.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more AnaptysBio Charts.